Angela Fleischman

Translational #MPN physician-scientist, interested in inflammation in MPN. Tweets are my own thoughts and opinions

[Liz Brem, MD @DrLizBrem]

If you are in SoCal, consider joining us @HiltonHB on Saturday, 1/19 to hear what colleagues and I from @ucirvinehealth and @chocchildrens think may be practice-changing from #ASH18. @MOASC_Office will provide CME credit and cocktails for your time! https://t.co/MgpkXcUlai

[Naveen Pemmaraju, MD @doctorpemm]

#ASH18 | Congratulations 🎉🎈🎊 to Dr Angela Fleischman @MPNlab winning #MPNHero award! @cure_magazine @mpncare @doctorpemm @ScottHamilton84 | @MPN_RF @mpnadvocacy @PatientPower @andrewschorr @PVReporter @mpndoc @AaronGerds @lauracmichaelis @mpdrc @RobynScherber | #MPNSM

[Angela Fleischman @MPNlab]

@OncologyTimes A5: Identification of more tumor associated antigens such as the novel peptide generated from calreticulin mutation in myeloproliferative neoplasm would be ideal targets. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A4: Immunotherapy at the present time is not a replacement for transplantation but can put someone in a CR such that they can move on to transplant. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A4: Immunotherapy such as CAR-T cells can be used as a bridge to transplant. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A5: I see it expanding to more novel targets in both solid and hematologic malignancies. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A3: Many new and exciting immunotherapy combinations are being investigated, but it is important to note that combos may increase response rates but also may add on additional toxicities as well as cost. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A3: Combination therapies using a PD-1 pathway inhibitor are currently utilized and have proven to be useful and new combos will likely to be developed with PD-1 inhibitors. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A2: Proteins that are present on tumor cells but not normal cells are ideal targets for immunotherapies such as CAR-T cell therapy. The calreticulin mutations in myeloproliferative neoplasm generates a novel peptide unique to the mutant cells which is ideal target. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A2: Within the hematologic malignancies lymphoid malignancies appear to be particularly amenable to immunotherapies. Within the solid tumors lung and melanoma appear to be particularly amenable to immunotherapies. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A1: The third unique feature is established cell surface antigens to target. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A1: Second is cells of the immune system and hematologic malignancy cells are in constant contact with each other within the hematopoietic system, making the environment conducive to constant immune surveillance. #HemOncChat

[Angela Fleischman @MPNlab]

@OncologyTimes A1: There are some unique features of hematologic malignancies that makes them cancers particularly well suited as targets of immunotherapy. First is sensitivity to immune attack. #HemOncChat

[Angela Fleischman @MPNlab]

@sslago1974

[Oncology Tube @oncologytube]

#Trametinib Early Study Shows Impressive Results for #MPN https://t.co/T0c3IoiOy2 @MPNlab @MOASC_Office #CancerResearch #MPNs #mpnsm #ASH

[Anna Deveau @focusblood]

The importance of non-pharmacological interventions in myeloproliferative neoplasms by Ruben Mesa https://t.co/DSDQcLLePf via @VJHemOnc

[Angela Fleischman @MPNlab]

@doctorpemm #MPN clinical trial now open, LCL-161 makes cells sensitive to killing by TNFalpha https://t.co/CFDZY3Bsui

[Angela Fleischman @MPNlab]

#ASH2014 mutated calreticulin in mouse model causes a disease resembling ET/MF https://t.co/RkRaXNHBUy

[Angela Fleischman @MPNlab]

#ASH14 My first tweet! Follow me for updates in MPN translational research. Inspired to start tweeting by @doctorpemm